Profile data is unavailable for this security.
About the company
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).
- Revenue in USD (TTM)7.00k
- Net income in USD-21.69m
- Incorporated2019
- Employees18.00
- LocationBenitec Biopharma Inc3940 Trust WayHAYWARD 94545United StatesUSA
- Phone+1 (510) 780-0819
- Fax+1 (302) 636-5454
- Websitehttps://benitec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chimerix Inc | 41.00k | -82.59m | 77.93m | 72.00 | -- | 0.4476 | -- | 1,900.81 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Ikena Oncology Inc | 3.85m | -70.09m | 78.66m | 34.00 | -- | 0.5064 | -- | 20.44 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
PMV Pharmaceuticals Inc | 0.00 | -65.10m | 80.25m | 63.00 | -- | 0.3773 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Checkpoint Therapeutics Inc | 68.00k | -52.32m | 80.33m | 23.00 | -- | -- | -- | 1,181.38 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -66.03m | 80.84m | 41.00 | -- | 0.7306 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Aclaris Therapeutics Inc | 31.12m | -77.26m | 81.95m | 91.00 | -- | 0.577 | -- | 2.63 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Benitec Biopharma Inc | 7.00k | -21.69m | 82.81m | 18.00 | -- | 2.09 | -- | 11,829.79 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Allovir Inc | 0.00 | -179.53m | 84.53m | 112.00 | -- | 0.7011 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 85.05m | 9.00 | -- | 4.31 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
Citius Pharmaceuticals Inc | 0.00 | -37.35m | 87.70m | 22.00 | -- | 0.973 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Vistagen Therapeutics Inc | 1.06m | -29.36m | 89.45m | 39.00 | -- | 0.7827 | -- | 84.07 | -2.12 | -2.12 | 0.055 | 4.23 | 0.0147 | -- | -- | 27,282.05 | -40.57 | -62.84 | -43.48 | -68.03 | -- | -- | -2,759.59 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
Adicet Bio Inc | 0.00 | -139.79m | 89.57m | 143.00 | -- | 0.3461 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Annovis Bio Inc | 0.00 | -47.53m | 90.27m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 22 Apr 2024 | 1.69m | 18.06% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 588.31k | 6.28% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 244.49k | 2.61% |
Adage Capital Management LPas of 31 Mar 2024 | 189.19k | 2.02% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 16.70k | 0.18% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 11.80k | 0.13% |
Geode Capital Management LLCas of 31 Mar 2024 | 10.02k | 0.11% |
GAMMA Investing LLCas of 31 Mar 2024 | 3.55k | 0.04% |
Tower Research Capital LLCas of 31 Mar 2024 | 1.75k | 0.02% |
UBS Securities LLCas of 31 Mar 2024 | 510.00 | 0.01% |